Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer
Pilot Study Of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation For Pediatric Hematopoietic Malignancies
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer
Pilot Study Of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation For Pediatric Hematopoietic Malignancies
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Screening Individuals and Families at High Risk for Hematologic Cancers
Clinical, Laboratory And Epidemiologic Characterization Of Individuals And Families At High Risk Of Hematologic Cancer
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Screening Individuals and Families at High Risk for Hematologic Cancers
Clinical, Laboratory And Epidemiologic Characterization Of Individuals And Families At High Risk Of Hematologic Cancer
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase I & II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase I & II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Safety Study of Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Treat Relapsed EBV-Positive Lymphoma,
The Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma.
Status: Archived
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
Safety Study of Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Treat Relapsed EBV-Positive Lymphoma,
The Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma.
Status: Archived
Updated: 1/1/1970
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
Safety Study of Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Treat Relapsed EBV-Positive Lymphoma,
The Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma.
Status: Archived
Houston Methodist Hospital
mi
from
Houston, TX
Safety Study of Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Treat Relapsed EBV-Positive Lymphoma,
The Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma.
Status: Archived
Updated: 1/1/1970
Houston Methodist Hospital
mi
from
Houston, TX
Safety Study of Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Treat Relapsed EBV-Positive Lymphoma,
The Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma.
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Safety Study of Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Treat Relapsed EBV-Positive Lymphoma,
The Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma.
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
Second Autologous Stem Cell Transplant in Treating Patients With Persistent or Recurrent Primary Systemic (AL) Amyloidosis
Phase II Trial of Second Autologous Transplantation in AL Amyloidosis
Status: Archived
Boston Med Center
mi
from
Boston, MA
Second Autologous Stem Cell Transplant in Treating Patients With Persistent or Recurrent Primary Systemic (AL) Amyloidosis
Phase II Trial of Second Autologous Transplantation in AL Amyloidosis
Status: Archived
Updated: 1/1/1970
Boston Med Center
mi
from
Boston, MA
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Phase II Study of the Efficacy and Toxicity of Ontak (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Phase II Study of the Efficacy and Toxicity of Ontak (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
NK Cell Transplantation for AML
Pilot Study Of Haplo-Identical Natural Killer Cell Transplantation For Acute Myeloid Leukemia
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
NK Cell Transplantation for AML
Pilot Study Of Haplo-Identical Natural Killer Cell Transplantation For Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies
Status: Archived
Children's Healthcare of Atlanta at Egleston - Pediatric Cardiac Intensive Care Unit
mi
from
Atlanta, GA
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies
Status: Archived
Updated: 1/1/1970
Children's Healthcare of Atlanta at Egleston - Pediatric Cardiac Intensive Care Unit
mi
from
Atlanta, GA
UCN-01 and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
Status: Archived
Greenebaum Cancer Center - University of Maryland
mi
from
Baltimore, MD
UCN-01 and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
Status: Archived
Updated: 1/1/1970
Greenebaum Cancer Center - University of Maryland
mi
from
Baltimore, MD
UCN-01 and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
UCN-01 and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulinâ„¢) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)
Status: Archived
James P. Wilmot Cancer Center, University of Rochester
mi
from
Rochester, NY
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulinâ„¢) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)
Status: Archived
Updated: 1/1/1970
James P. Wilmot Cancer Center, University of Rochester
mi
from
Rochester, NY
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
Immuno-Augmentation With GM-CSF in Patients Receiving Pneumococcal Vaccine While Undergoing Treatment for Advanced Chronic Lymphocytic Leukemia (CLL)
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
Immuno-Augmentation With GM-CSF in Patients Receiving Pneumococcal Vaccine While Undergoing Treatment for Advanced Chronic Lymphocytic Leukemia (CLL)
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Children's Hospital
mi
from
Pittsburgh, PA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Children's Hospital
mi
from
Pittsburgh, PA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Lucile Salter Packer Children's Hospital at Stanford University Medical Center
mi
from
Palo Alto, CA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Lucile Salter Packer Children's Hospital at Stanford University Medical Center
mi
from
Palo Alto, CA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
State University of New York - Erie Country Medical Center
mi
from
Buffalo, NY
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
State University of New York - Erie Country Medical Center
mi
from
Buffalo, NY
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Archived
Updated: 1/1/1970
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
St. Vincent's Hospital
mi
from
Los Angeles, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
St. Vincent's Hospital
mi
from
Los Angeles, CA
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Rituximab for Prevention of Chronic GVHD
A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Rituximab for Prevention of Chronic GVHD
A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase II Trial of Triapine (IND # 68338, NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase II Trial of Triapine (IND # 68338, NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
Phase I/II Study of Clofarabine Plus Cyclophosphamide for Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
Phase I/II Study of Clofarabine Plus Cyclophosphamide for Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Oncotherapeutics
mi
from
West Hollywood, CA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Oncotherapeutics
mi
from
West Hollywood, CA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Rocky Mountain Cancer Center
mi
from
Denver, CO